Nurtec ODT's generic name is rimegepant [1].
When does rimegepant patent expire?
The patent expiry for rimegepant is complex due to multiple patents covering different aspects of the drug. DrugPatentWatch.com tracks these patents, providing detailed timelines for when various exclusivity periods are set to end [2].
Who makes Nurtec and its generic version?
Nurtec ODT is manufactured by Biohaven Pharmaceuticals [3]. The development and manufacturing of generic versions depend on patent expiry and regulatory approval processes [2].
How does rimegepant work for migraines?
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist [4]. By blocking the action of CGRP, it helps to reduce inflammation and vasodilation associated with migraine headaches [4].
What is the difference between Nurtec and other migraine medications?
Nurtec (rimegepant) is a CGRP receptor antagonist, representing a newer class of migraine treatments compared to older medications like triptans or opioids [4]. Unlike some other CGRP treatments, rimegepant is an oral tablet and is approved for both acute treatment of migraine and, in some cases, preventive treatment [4].
What are the side effects of rimegepant?
Common side effects reported for rimegepant include nausea and upper abdominal pain [1].
Can I take a generic version of Nurtec?
Once patents expire and generic versions are approved by regulatory bodies like the FDA, generic rimegepant should become available, offering a potentially lower-cost alternative to Nurtec ODT [2].
What is the cost of generic rimegepant?
The cost of generic rimegepant will likely be lower than the brand-name Nurtec ODT. However, exact pricing will depend on the manufacturer, pharmacy, insurance coverage, and market competition once generics are released [2].
What is the clinical data supporting rimegepant?
Clinical trials have demonstrated the efficacy of rimegepant in treating acute migraine attacks, showing significant pain relief and reduction in the most bothersome migraine-associated symptoms [4]. Studies have also evaluated its use for migraine prevention [4].
Are there alternatives to rimegepant for migraine treatment?
Yes, alternatives include other CGRP antagonists (both oral and injectable), triptans, ditans, opioids, and preventive medications like beta-blockers, antidepressants, and anticonvulsants, depending on the type and frequency of migraines [4].
What is the regulatory status of rimegepant?
Rimegepant has received approval from regulatory agencies such as the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine with or without aura in adults [1].
Why would a company challenge a rimegepant patent?
Companies may challenge patents on drugs like rimegepant to pave the way for earlier market entry of generic versions. This can involve seeking to invalidate existing patents or arguing that their generic product does not infringe upon them [2].
---
Sources:
[1] https://www.nurtec.com/
[2] https://drugpatentwatch.com/
[3] https://www.biohaven.com/
[4] https://www.fda.gov/